Chronic kidney disease (CKD) is prevalent and affects an ever-increasing proportion of patients presenting with acute coronary syndrome (ACS). Patients with CKD have a higher risk of ACS and significantly higher mortality, and are also predisposed to increased bleeding complications. Antiplatelet and antithrombotic drugs form the bedrock of management of patients with ACS. Most randomized trials of these drugs exclude patients with CKD, and current guidelines for management of these patients are largely based on these trials. We aim to review the safety and efficacy of these drugs in patients with CKD presenting with ACS. (J Am Coll Cardiol 2011;58:2263-9) 
Chronic kidney disease (CKD) as defined by the National Kidney Foundation includes a mild reduction of glomerular filtration rate (GFR) in the presence of kidney damage (stage 2), and moderate to severe reductions in GFR even in the absence of kidney damage (stages 3 to 5) ( Table 1) . The National Kidney Foundation estimates that 11% of the U.S. population has CKD (1). Data from clinical trials suggest that 35% to 40% of patients presenting with an acute coronary syndrome (ACS) have some degree of renal insufficiency (2, 3) . Chronic kidney disease is an independent predictor of outcome in patients presenting with ACS. Cardiovascular disease is the leading cause of death in patients with CKD (1, 4) .
Patients with renal insufficiency are known to have a graded increased risk for thrombosis (5) and bleeding (6, 7) . Uremia is associated with prolongation of bleeding time and abnormal platelet aggregation and adhesion due to intrinsic and extrinsic factors ( Fig. 1) (8) . The American College of Cardiology (ACC) and American Heart Association (AHA) guidelines for management of ACS clearly acknowledge the lack of sufficient studies so as to make specific recommendations for patients with CKD (9) . A recent study showed that patients with CKD were excluded from 75% of published coronary artery disease trials (10) . It is extremely important for practitioners to become familiar with the sites of action of all the antiplatelet and antithrom-botic drugs, as shown in Figure 2 , to make judicial decisions regarding CKD patients. Table 2 also shows the recommended dose, half-life, route of elimination, and dose adjustment of most approved anticoagulants, as well as potential methods to reverse bleeding for each of these agents.
Antiplatelet and Antithrombotic Drugs
The antiplatelet and antithrombotic drugs used for treating patients with CKD are shown in Table 3 . Aspirin. The efficacy of aspirin for patients with CKD presenting with ACS is well established. In the Cooperative Cardiovascular Project (11), McCullough et al. (12) showed that aspirin reduced in-hospital mortality by 64.3% to 80% across all quartiles of creatinine clearance (CrCl). In addition, patients who were not receiving aspirin on admission were more likely to be in heart failure or cardiogenic shock. A recent retrospective review of 595 patients with ACS found that the use of aspirin was associated with a decreased rate of ST-segment elevation myocardial infarction in patients with GFR Ͻ60 ml/min (odds ratio [OR]: 0.5, 95% confidence interval [CI]: 0.2 to 1.0; p ϭ 0.05) (13) . Data from the National Cardiovascular Data ACTION (Acute Coronary Treatment and Intervention Outcomes Network) registry, including 19,029 patients with ST-segment elevation myocardial infarction and 30,462 with non-STsegment elevation myocardial infarction, documented decreasing use of aspirin with worsening severity of CKD (14, 15) . The U.K. HARP (Heart and Renal Protection)-1 trial and the DOPPS (Dialysis Outcomes and Prescription Patterns Study) showed that low-dose aspirin (100 mg/day) in CKD patients was not associated with increased major bleeding or progression of CKD (16, 17) . In a recent meta-analysis by the Antithrombotic Trialists Collaboration, low-dose aspirin (75 to 160 mg) was found to be as efficacious as high-dose aspirin (325 mg) beyond the acute phase for secondary prevention of coronary artery disease in patients with CKD and end-stage renal disease (18) . Clopidogrel. The current ACC/ AHA guidelines recommend the use of clopidogrel in patients with ACS (9, 19) . No specific recommendations exist for the adjustment of clopidogrel dosage in renal insufficiency. A post-hoc analysis from the CREDO (Clopidogrel for Reduction in Events During Observation) trial, patients with mild and moderate CKD did not have any significant difference in outcomes (mild 10.3 % vs. 12.8%, p ϭ 0.30; moderate 17.8% vs. 13.1%, p ϭ 0.24) with increased risk of bleeding with clopidogrel (20) .
A post-hoc analysis of the CURE (Clopidogrel in Unstable Angina to Prevent Recurrent Events) trial (21) (22) (23) showed no interaction between clopidogrel and renal function (p value for homogeneity 0.11). However, there was no significant benefit from using clopidogrel for patients in the lowest tertile (relative risk: 0.89 [95% confidence interval [CI]: 0.76 to 1.05]), and patients in this group had a significant increase in minor bleeding (hazard ratio: 1.5, 95% CI: 1.21 to 1.86) and blood transfusion (3.5%).
Deray et al. (24) , compared platelet inhibition using 75 mg of clopidogrel in patients with moderate and severe CKD, and demonstrated similar clopidogrel-induced platelet inhibition in both groups. Park et al. (25) compared clopidogrel responsiveness in normal persons (n ϭ 23) and patients with CKD treated with 75 mg (n ϭ 18) and 150 mg (n ϭ 18) of clopidogrel. They found decreased platelet inhibition in patients with CKD even with doubling the dose of clopidogrel (25) . A recent study by Cuisset et al. (26) evaluated the effect of CKD on platelet aggregation in patients with ACS given clopidogrel (600 mg loading dose followed by 150 mg daily). There was no difference in platelet aggregation acutely and at 30 days. Clinical effect of CKD in patients administered double-dose clopidogrel in the OASIS-7 (Seventh Organization to Assess Strategies in Acute Coronary Syndrome) trial is not available. Prasugrel. Prasugrel is a third-generation thienopyridine (27) (28) (29) . Small et al. (30) conducted a study comparing the pharmacokinetics and pharmacodynamics of prasugrel in patients with normal renal function, moderate renal insufficiency, and end-stage renal disease. The levels of the active metabolite of prasugrel were not affected by moderate renal impairment, but decreased by 40% in end-stage renal disease, although with similar platelet inhibition levels. Inhibition of platelet aggregation was similar in all groups (30) . So far, there are no studies on clinical outcomes with prasugrel in patients with CKD. Ticagrelor. Ticagrelor is a more potent inhibitor of platelet aggregation (31, 32) . A subanalysis of the PLATO (Ticagrelor versus Clopidogrel in Patients in Acute Coronary Syndrome) trial showed CKD patients (GFR Ͻ60 ml; n ϭ 3,237) have a greater reduction in events (17.3% vs. 22%; hazard ratio: 0.77 [95% CI: 0.65 to 0.90]) and mortality (10% vs. 14%; hazard ratio: 0.72 [95% CI: 0.58 to 0.89]) as compared to non-CKD: 4.7% per year vs. 1% per year, respectively (34) . Ticagrelor offers an alternative option for treating ACS patients with CKD. Glycoprotein IIb/IIIa inhibitors. Intravenous glycoprotein IIb/IIIa inhibitors (GPIs) block the final pathway for platelet aggregation (34, 35) . Frilling et al. (36) compared the efficacy of abciximab in normal and CKD patients. Patients in either group had similar clinical outcomes. The CKD patients had more episodes of major bleeding (4.5% vs. 0.6%; p ϭ 0.003) but similar episodes of minor bleeding and thrombocytopenia. Similar findings were reported by the Mayo Clinic (37) . A recent study by Pinkau et al. (38) evaluated adding abciximab to aspirin and clopidogrel in CKD patients undergoing PCI. There was no significant interaction between abciximab, renal function, and bleeding complications (p ϭ 0.22). Alam et al. (38) showed that patients with CrCl Ͻ60 ml/min have Ͻ10% platelet aggregation at 25 ng/ml tirofiban, one-third the standard effective dose in non-CKD patients.
A subgroup analysis of the PRISM-PLUS (Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms) trial showed that TIMI (Thrombolysis In Myocardial Infarction) major bleeding was not significantly worsened by renal dysfunction or the use of tirofiban (p ϭ 0.35 and p ϭ 0.20, respectively). However, the combined endpoint of TIMI major and minor bleeding was increased with worsening renal function (p ϭ 0.004) as well as use of tirofiban (p ϭ 0.04).
A subanalysis of the TARGET (Do Tirofiban and ReoPro Give Similar Efficacy Outcome) trial (40) based on creatinine clearance (Ͻ70, 70 to 90, 90 to 114, and Ͼ114 ml/min) showed that patients with lower CrCl have higher ischemic and bleeding events. The ESPRIT (Enhanced National Kidney Foundation Classification of CKD Based on GFR 
Figure 2 Sites of Inhibition of Platelet Activation and Aggregation
The sites of inhibition of platelet activation and aggregation by all currently approved anticoagulants are detailed. ADP ϭ adenosine diphosphate; GP ϭ glycoprotein; TxA 2 ϭ thromboxane A 2 ; wWF ϭ von Willebrand factor. 2265 JACC Vol. 58, No. 22, 2011 Basra et al. November 22, 2011 November 22, :2263 Safety and Efficacy of Anticoagulants in Kidney Disease Suppress Adverse Outcomes With Early Implementation of the American College of Cardiology/American Heart Association Guidelines) National Quality Improvement Registry found that bleeding risk is higher in patients administered excess doses of GPIs (OR: 1.36; 95% CI: 1.10 to 1.68), and it is further increased in patients with renal insufficiency (OR 4.12; 95% CI: 2.65 to 5.75). These data further underscore the importance of calculating the CrCl before administering GPIs (45) . Heparin. Unfractionated heparin reduces early ischemic events in patients with ACS with and without CKD (45) (46) (47) (48) . The half-life of enoxaparin in dialysis patients is twice as long as in healthy volunteers. The total clearance of enoxaparin is 1.9 times lower and its half-life 1.7 times longer in patients with renal insufficiency (49 -57) . A retrospective study evaluated the outcomes of bleeding and death in patients with CKD administered enoxaparin demonstrated an increase in total bleeding, major bleeding as well as deaths (58) . A recent substudy of the EXTRACT (Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment)-TIMI 25 trial showed that with every 30 ml/min decrease in CrCl, the risk of major and minor bleeding increased by 50% (59) . Fondaparinux. Fondaparinux is a synthetic heparin analogue that causes an irreversible conformational change in antithrombin. Fondaparinux is given a class I ACC/AHA recommendation in ACS patients with high bleeding risk. In the OASIS-5 (Fifth Organization to Assess Strategies in Acute Coronary Syndrome) trial (59) , the composite endpoint was lower with fondaparinux compared to enoxaparin and reached significance only in patients with GFR Ͻ58 ml/min/1.73 m 2 . The rates of bleeding were lower across all quartiles of renal dysfunction. Bivalirudin. Bivalirudin is a synthetic direct thrombin inhibitor with a half-life of 25 min and significant renal clearance (62) (63) (64) . In a substudy of the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial (62) in CKD patients, there were fewer bleeding complications with bivalirudin than with unfractionated heparin plus GPI (65 
Conclusions
There is a clear dearth of studies evaluating the safety and efficacy of these drugs for treating CKD patients, and most of the recommendations are based on single-center data or post-hoc analyses. Novel therapies may help overcome some of the complications observed in these patients, but further randomized trials are warranted to objectively evaluate their efficacy for this increasingly common subgroup of patients. 2267 JACC Vol. 58, No. 22, 2011 Basra et al. November 22, 2011 November 22, :2263 Safety and Efficacy of Anticoagulants in Kidney Disease
